Reckitt Benckiser completes £1 billion buyback, shares steady on London Stock Exchange

Reckitt Benckiser has finished the third and final tranche of its £1 billion share buyback programme, repurchasing over 11 million shares at an average £48.55 and holding them in treasury, as London-listed shares trade largely stable ahead of interim results.

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 15:10.

Reckitt Benckiser Group plc (GB00B24CGK77) has confirmed the completion of the third and final tranche of its current £1 billion share buyback programme, with London-listed shares trading on the London Stock Exchange in a calm pattern as investors digest the capital return.

What the buyback completion shows

According to the company announcement on Investegate, Reckitt Benckiser launched the £1 billion buyback in July 2025 and has now fully executed it, with the last tranche completed between 9 March and 15 June 2026. Under this third tranche, the group repurchased 11,122,383 ordinary shares at an average price of £48.55, with all shares held in treasury rather than cancelled.

The programme followed the earlier divestment of Reckitt's Essential Home business, where the company agreed to return around US$2.2 billion to shareholders via a special dividend and share consolidation, subject to shareholder approval. In its latest capital allocation communication, Reckitt flagged that further details on potential new buyback programmes will be provided alongside interim 2026 results, scheduled for 29 July 2026.

Analyst focus and sector context

Analyst commentary in recent months has focused on valuation, capital returns and the health of Reckitt Benckiser's consumer brands compared with peers such as Unilever and Procter & Gamble. A recent Morgan Stanley update maintained an Overweight stance on Reckitt Benckiser Group while revising its price target downward from 6,200 GBp to 5,800 GBp, pointing to a more cautious view on near-term valuation despite long-term support for the stock.

The same analysis highlighted modest adjustments to fair value estimates and net profit margin assumptions, with long-term revenue growth projections around a low single-digit annualized decline and net margins near 17 percent, framing Reckitt Benckiser as a mature, cash-generative player in the global consumer health and hygiene segment. On the London Stock Exchange, MarketBeat price data recently showed Reckitt Benckiser shares around GBX 4,852, underlining a relatively stable trading range compared with other large-cap staples.

The product engine behind the numbers

Reckitt Benckiser makes its money primarily through a portfolio of branded consumer health, hygiene and nutrition products, with Powerbrands such as Dettol, Lysol, Nurofen, Durex and Finish forming the core of its business. In consumer health, Nurofen pain relief and Durex sexual wellness products contribute to high-margin categories, while in hygiene brands like Dettol and Lysol serve both developed and emerging markets.

Where the stock trades today

Reckitt Benckiser shares (GB00B24CGK77) trade on the London Stock Exchange at around 4,852 pence as of 2026-06-26, 13:10 London time, based on recent MarketBeat data. The London listing is the primary venue for the stock, which is part of the FTSE 100 index of large UK companies.

Reckitt Benckiser at a glance

• Company: Reckitt Benckiser Group plc
• ISIN: GB00B24CGK77
• WKN: A420TB
• Ticker: RKT
• Trading venue: London Stock Exchange
• Price (as of 2026-06-26, 13:10): 4,852 pence
• Market cap: approximately £34 billion (as of 2026-06-26, based on recent London trading data)
• Sector / industry: Consumer Staples / Household & Personal Products
• Index membership: FTSE 100
• Next earnings date: 2026-07-29

This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell any financial instrument. All data are based on sources believed to be reliable but cannot be guaranteed.